{
    "clinical_study": {
        "@rank": "119198", 
        "acronym": "CT05", 
        "arm_group": [
            {
                "arm_group_label": "CHF 5074 1x", 
                "arm_group_type": "Experimental", 
                "description": "oral tablet, multidose"
            }, 
            {
                "arm_group_label": "CHF 5074 2x", 
                "arm_group_type": "Experimental", 
                "description": "oral tablet, multidose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo, oral tablet, multidose"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effects of multiple dose regimens of CHF 5074 administered once per day up\n      to 2 years on potential biomarkers of neurodegeneration in subjects with mild cognitive\n      impairment."
        }, 
        "brief_title": "Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Nerve Degeneration", 
                "Cognition Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  One or two \u01904 alleles of the apolipoprotein E (APOE) gene.\n\n          -  Diagnosis of amnestic Mild Cognitive Impairment.\n\n          -  Mini-Mental State Examination score higher than 24 at screening.\n\n        Exclusion Criteria:\n\n          -  Diagnosis of Alzheimer's disease.\n\n          -  Any medical condition that could explain the subject's cognitive deficits.\n\n          -  MRI scans having evidence of pre-specified brain abnormalities.\n\n          -  History of stroke.\n\n          -  Vitamin B12 or folate deficiency.\n\n          -  Skin cancers and any cancer that is being actively treated.\n\n          -  Diagnosis of schizophrenia or recurrent mood disorder.\n\n          -  Abnormal kidney function.\n\n          -  Concomitant use of any study prohibitive medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723670", 
            "org_study_id": "CCD-1109-PR-0072"
        }, 
        "intervention": [
            {
                "arm_group_label": "CHF 5074 1x", 
                "description": "oral tablet, 1x, once a day for 24 months", 
                "intervention_name": "CHF 5074 1x", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CHF 5074 2x", 
                "description": "oral tablet, 2x, once a day for 24 months", 
                "intervention_name": "CHF 5074 2x", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "oral tablet,once a day for 24 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 20, 2012", 
        "number_of_arms": "3", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Multiple Dose Regimens of CHF 5074 for up to 2 Years on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment", 
        "other_outcome": [
            {
                "description": "rate of cognitive decline", 
                "measure": "Change from baseline in cognitive performance", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, Month 6, Month 12, Month18, Month 24"
            }, 
            {
                "measure": "Change from baseline in global clinical status", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, Month 6, Month 12, Month 18, Month 24"
            }
        ], 
        "overall_official": {
            "affiliation": "Memory Enhancement Center of America", 
            "last_name": "Joel S Ross, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To determine the effects on change from baseline on brain atrophy", 
            "safety_issue": "No", 
            "time_frame": "pre-dose, Months 6, 12, 18, 24 and Washout"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723670"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To determine the presence of other biomarkers of neuronal degeneration", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "To determine the presence of other biomarkers of neuronal degeneration", 
                "safety_issue": "No", 
                "time_frame": "Month 24"
            }
        ], 
        "source": "Chiesi Pharmaceuticals Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}